PMID: 9171951Jun 1, 1997Paper

Nitric oxide synthase inhibition with N omega-nitro-L-arginine methyl ester affects blood pressure and cardiovascular structure in the genetically hypertensive rat strain

Clinical and Experimental Pharmacology & Physiology
J M Ledingham, R Laverty

Abstract

1. Inhibition of nitric oxide (NO) synthesis with the nitric oxide synthase (NOS) inhibitor N omega-nitro-L-arginine methyl ester (L-NAME) was used as a tool to investigate further a possible endothelial defect in the New Zealand genetically hypertensive (GH) rat strain compared with its normotensive (N) control strain. 2. N omega-nitro-L-arginine methyl ester was given to GH and N groups in their drinking water from age 7-10 weeks (10 mg/kg per day for week 1 and 2 and then 5 mg/kg per day for week 3). Tailcuff blood pressure (BP) was measured weekly and at the end of the experiment the mesentery was fixed by perfusion, second order branches of the mesenteric artery were embedded in Technovit and stained sections were used to quantify the structure of the mesenteric resistance arteries (MRA). The heart was removed and weighed for determination of left ventricular (LV) mass. 3. In GH rats, BP and LV mass were significantly raised by L-NAME, while in N rats L-NAME treatment significantly elevated BP, but had no effect on LV mass. 4. In GH rats, the media width was significantly increased by L-NAME treatment (P < 0.01); lumen diameter remained unchanged. Thus, the ratio of media width/lumen diameter (M/L) was significantly increa...Continue Reading

References

Jul 5, 1990·The New England Journal of Medicine·J A PanzaS E Epstein
Oct 1, 1988·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·H J GundersenB Pakkenberg
Jun 1, 1986·Hypertension·W LocketteO Carretero
May 1, 1988·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·H J GundersenA Vesterby
Nov 1, 1986·Hypertension·J K MurphyG W Somes
Oct 1, 1984·Journal of Hypertension·R J WinquistA A Wallace
May 1, 1993·Clinical and Experimental Pharmacology & Physiology·J M Ledingham, J A Millar

❮ Previous
Next ❯

Citations

Jun 30, 2000·Clinical and Experimental Pharmacology & Physiology·S J OrangeR Laverty
May 16, 2002·Clinical and Experimental Pharmacology & Physiology·Hanzhong LiuRichard Laverty
Feb 25, 2003·Journal of Smooth Muscle Research = Nihon Heikatsukin Gakkai Kikanshi·Fumiko SekiguchiSatoru Sunano
Jul 20, 2000·Clinical and Experimental Pharmacology & Physiology·E J TuckerR Laverty
Jul 21, 2012·Pharmacological Reports : PR·Jana KopincováIveta Bernátová

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Cardiovascular Homeostasis

Cardiovascular regulation and homeostasis is important in maintaining health and dysfunction may lead to cardiovascular diseases. Nitric oxide and vascular endothelium are one of many molecules involved in the homeostatic mechanism. Here is the latest research on cardiovascular homeostasis.